E-CEF ( POWDER, INJECTION ) ( 250 mg )

Manufacturer
Lupin Laboratories
Drug Type
 Branded Drug
Medicine System
 Allopathy
Drug Availability
 Pharmacy (P)

Ingredients

SKU

Brand NameDosage Form PackQty per PackInquiry
E-CEF INJPOWDER, INJECTION1 Please Inquire

Related Generic Drugs

Related Monographs

Ceftriaxone

Pregnancy Category B

Essential Medicine :

Schedule Drug Category: H

Usage / Indications

  • Serious infections due to sensitive bacteria, including septicaemia, pneumonia and meningitis
  • Surgical prophylaxis
  • Prophylaxis of meningococcal meningitis
  • Gonorrhea
  • Bone and joint infection.

Dosage

Source : IAP Pediatric Drug Formulary
Neonates 50-75 mg/kg once daily IM/IV. Infuse over 10-30 min. Avoid in premature, acidotic or hyperbilirubinemic neonates. Children 50-75 mg/kg once daily IV/IM. Meningities loading dose 75mg/kg followed by 80-100mg/kg24 hrs once or divided 12hrly. Maximum 4gm/day. In severe renal failure reduce dose to a maximum of 2g or 50mg/kg. No dose adjustment required in hepatic impairment. If both hepatic and severe renal impairment monitor serum concentrations. In patients undergoing dialysis no supplemental dose required but serum concentration monitoring advisable.

Source : NFI National Formulary of India
Intramuscular and intravenous injection or infusion

Adult- Urinary tract infection, pneumonia, pelvic inflammatory disease, prophylaxis of surgical infections and meningitis: 4g initially once daily for 10 days or up to 72 h after fever disappears.

Typhoid: 4g daily for two days followed by 2g daily for next two days. 1 to 2g daily is used for any other type of condition.

Child- Meningitis: 75 to 100 mg/kg body weight for 7 to 9 days.

Typhoid: 5 mg/kg body weight for 7 days. 50 to 75 mg/kg body weight is used in case of any other condition (max 2g/day).

Contraindications

  • Cephalosporin hypersensitivity
  • Porphyria
  • Neonates with jaundice, hypoalbuminaemia, acidosis or impaired bilirubin binding

Precautions

  • Penicillin sensitivity
  • Severe renal impairment
  • Hepatic impairment if accompanied by renal impairment
  • Premature neonates
  • May displace bilirubin from serum albumin
  • Treatment longer than 14 days, renal failure, dehydration or concomitant total parenteral nutrition-risk of ceftriaxone precipitation in gallbladder
  • Lactation (but appropriate to use)
  • Pregnancy
  • False positive urinary glucose (if tested for reducing substances) and false positive Coombs’ test
  • Interactions
  • Phrophylactic indication, patients with impaired vit K synthesis, monitoring of prothrombin time is recommended.

Side Effects / Adverse Effects

  • Diarrhoea, nausea and vomiting, abdominal  discomfort, headache
  • Antibiotic-associated  colitis (particularly with higher doses)
  • Allergic reactions including rashes, pruritus,  urticaria, serum sickness-like reactions,  fever and arthralgia and anaphylaxis
  • Erythema multiforme, toxic epidermal necrolysis reported
  • Transient hepatitis and cholestatic jaundice
  • Elevation of SGOT and SGPT
  • Eosinophilia and blood disorders (including thrombocytopenia, leukopenia, agranulocytosis, aplastic anaemia and haemolytic anaemia)
  • Reversible interstitial nephritis, hyperactivity, nervousness, sleep disturbances, confusion, hypertonia and dizziness
  • Calcium ceftriaxone precipitates in urine (particularly in very young, dehydrated, or those who are immobilized) or in gall bladder-consider discontinuation if symptomatic
  • Rarely, prolongation of prothrombin time, pancreatitis
  • Local reaction, hypersensitivity.

Storage

Store protected from light at a temperature not exceeding 30⁰C

Disclaimer:

Every effort has been made to ensure that the information provided by HealthKonnect is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource.This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. HealthKonnect India Pvt Ltd does not assume any responsibility for any aspect of healthcare administered with the aid of information HealthKonnect provides.The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor or pharmacist.

The Price of the drugs indicated above may not match the actual price at which they are sold. Prices can change depending on many factors, including local taxes. These are only approximate indicative prices of the drug.

Loading ...